Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Outcome disparities across different subgroups in clinical trials: chance or biological?

Edward Cliff • 10 Dec 2023
ASH 2023
General

Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, highlights key considerations for depicting whether disparities in outcomes among subgroups in clinical trials stem from chance or genuine biological distinctions. He emphasizes the importance of pre-specifying subgroup analyses, the need for replication across studies, the persistence of differences after covariate adjustments, and, crucially, a biological rationale that supports the observed distinctions. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Edward Cliff

1:32
Subgroup classification in DLBCL: barriers and considerations
Edward Cliff • 10 Dec 2023
1:41
POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin
Edward Cliff • 10 Dec 2023
2:31
Cost-effectiveness analysis of CAR-T therapy
Edward Cliff • 3 Jun 2023
3:49
Strategies to improve cost & access to CAR-T therapy
Edward Cliff • 3 Jun 2023

Related Videos

2:14
The influence of graft source and composition on GvHD
Mattia Algeri • 15 Apr 2024
1:49
Guidelines on the diagnosis and management of neutropenia
Carlo Dufour • 15 Apr 2024
1:51
The importance of sustainable healthcare
Shireen Kassam • 24 Apr 2024
2:20
EBMT diagnostic criteria for TMA post-alloSCT and the role of complement activation
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals